---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-001745"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2021-09-09T23:59:59+00:00"
generated_at: "2026-06-29T04:55:29.456826+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Janux Therapeutics appoints Ronald Barrett and Alana McNulty as directors

## Summary
- Ronald Barrett, Ph.D. appointed as Class I director with term expiring at 2022 annual meeting.
- Alana McNulty appointed as Class II director with term expiring at 2023 annual meeting.
- Each receives $40,000 annual cash retainer and option to purchase 30,000 shares vesting over 3 years.

## SEC filing metadata
- accession: 0000950170-21-001745
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2021-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017021001745/0000950170-21-001745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017021001745/janx-20210907.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-001745
- JSON: https://secwatch.observer/filing/0000950170-21-001745.json
- Plain text: https://secwatch.observer/filing/0000950170-21-001745.txt

## Key facts
- Executive change
  Alana McNulty was appointed as Class II director at Janux Therapeutics, Inc..
  - Action: appointed
  - Role: Class II director
  source text: appointed (i) Ronald Barrett, Ph.D. as a Class I director of the Company, with a term of office expiring at the 2022 annual meeting of stockholders, and (ii) Alana McNulty as a Class II director of the Company, with a term of office expiring at the 2023 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017021001745/0000950170-21-001745-index.htm
- Executive change
  Ronald Barrett was appointed as Class I director at Janux Therapeutics, Inc..
  - Action: appointed
  - Role: Class I director
  source text: appointed (i) Ronald Barrett, Ph.D. as a Class I director of the Company, with a term of office expiring at the 2022 annual meeting of stockholders, and (ii) Alana McNulty as a Class II director of the Company, with a term of office expiring at the 2023 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017021001745/0000950170-21-001745-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.